Nanotechnology in Drug Delivery for Liver Fibrosis

Gu, Lihong; Zhang, Feng; Wu, Jinhui; Zhuge, Yuzheng

doi:10.3389/fmolb.2021.804396

Cited by 27 publications

(20 citation statements)

References 106 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As negatively charge nanoparticles and particles larger than 200 nm are removed from the system, this puts a constraint on the physicochemical characteristics of the nanocarrier for mRNA. 87 Various methods have been developed to enhance the delivery of mRNA into hepatocytes. By utilizing the mannose receptors on LSECs, mannose-modified lipid nanoparticles have shown to accumulate in the liver in an in vivo study.…”

Section: Function and Structure Of The Livermentioning

confidence: 99%

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

2023

View full text Add to dashboard Cite

show abstract

Section: Function and Structure Of The Livermentioning

confidence: 99%

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

2023

View full text Add to dashboard Cite

show abstract

“…Nanotechnology in drug delivery offers an exciting and promising field of research for the treatment of chronic liver diseases. Several metal, lipid, polymer, and protein nanoparticles with enhanced features such as prolonged circulation, improved internalization, and pharmacokinetics and reduced toxicity have been developed for treating liver fibrosis 189 . As organelles are prime therapeutic targets in various pathophysiological conditions, including liver fibrosis, the concept of organelle-targeting is gaining increasing attention.…”

Section: An Organellar Approach For Treating Liver Fibrosis: Are We G...mentioning

confidence: 99%

Organelle stress and alterations in interorganelle crosstalk during liver fibrosis

2023

View full text Add to dashboard Cite

The synchronous functioning and quality control of organelles ensure cell survival and function and are essential for maintaining homeostasis. Prolonged exposure to stressors (viruses, bacteria, parasitic infections, alcohol, drugs) or genetic mutations often disrupt the functional integrity of organelles which plays a critical role in the initiation and progression of several diseases including chronic liver diseases. One of the most important pathologic consequences of chronic liver diseases is liver fibrosis, characterized by tissue scarring due to the progressive accumulation of extracellular matrix components. Left untreated, fibrosis may advance to lifethreatening complications such as cirrhosis, hepatic decompensation, and HCC, which collectively accounts for ∼1 million deaths per year worldwide.Owing to the lack of treatment options that can regress or reverse cirrhosis, liver transplantation is currently the only available treatment for end-stage liver disease. However, the limited supply of usable donor organs, adverse effects of lifelong immunosuppressive regimes, and financial considerations pose major challenges and limit its application. Hence, effective therapeutic strategies are urgently needed. An improved understanding of the organellelevel regulation of fibrosis can help devise effective antifibrotic therapies focused on reducing organelle stress, limiting organelle damage, improving interorganelle crosstalk, and restoring organelle homeostasis; and could be a potential clinical option to avoid transplantation. This review provides a timely update on the recent findings and mechanisms covering organelle-

show abstract

“…Similar to the approaches for designing therapeutic peptides, targeting peptides can also be designed by high throughput screening approaches. Conjugating the screened targeting peptides to the surface of nanomaterials provides an efficient method to produce positive targeting nanomaterials [2a,11] …”

Section: Introductionmentioning

confidence: 99%

Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis

Huang

Zou

2023

ChemBioChem

View full text Add to dashboard Cite

Liver fibrosis is a process of excessive accumulation of extracellular matrix caused by liver injury. Liver fibrosis can progress to cirrhosis or even liver cancer without proper intervention. Until now, no effective therapeutic drugs have been clinically approved for treating liver fibrosis. Hence, the development of safe and effective antifibrotic drugs is particularly important. As a representative biomaterial, peptides have been investigated as key components for constructing antifibrotic nanomaterials given their advantages of biological origination, synthetic availability, and good biocompatibility. Peptides serve as multifunctional motifs in antifibrotic nanomaterials, such as liver‐targeting molecules, antifibrotic molecules, and self‐assembling building blocks for the formation of the nanomaterials. In this review, we focus on peptide‐based nanoarchitectonics for treating liver fibrosis, including nanomaterials modified with liver‐targeting peptides, nanomaterials for the efficient delivery of antifibrotic peptides, and self‐assembled peptide nanomaterials for the delivery of antifibrotic drugs. The design rules of these peptide‐based nanomaterials are described. The antifibrotic mechanisms and effects of these peptide‐based nanomaterials in treating liver fibrosis and related diseases are highlighted. The challenges and future perspectives of using peptide‐based nanoarchitectonics for the treatment of liver fibrosis are discussed. These results are expected to accelerate the rational design and clinical translation of antifibrotic nanomaterials.

show abstract

Nanotechnology in Drug Delivery for Liver Fibrosis

Cited by 27 publications

References 106 publications

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

Advances in nanoparticle-based mRNA delivery for liver cancer and liver-associated infectious diseases

Organelle stress and alterations in interorganelle crosstalk during liver fibrosis

Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis

Contact Info

Product

Resources

About